Navigation Links
d’Oliveira & Associates Releases New Webpage on Pradaxa Lawsuits
Date:3/6/2013

(PRWEB) March 06, 2013

Manufactured by Boehringer Ingelheim, Pradaxa is an anticoagulant drug that is used to treat a variety of blood and heart conditions*. In October 2010, the Food and Drug Administration (FDA) approved Pradaxa for sale on the market*. As reported by the NY Times, Pradaxa was marketed as a superior drug choice to Warfarin, but medical studies suggest that Pradaxa may be more dangerous than Warfarin*. The NY Times article goes on to explain that excessive bleeding from Warfarin can treated with Vitamin K, but the anticoagulant drug Pradaxa has no such treatment to counteract excessive bleeding*. The FDA lists the Pradaxa side effects that may include nosebleeds, discolored urine and stool, unusual hemorrhaging, headaches, and swelling**. More serious medical conditions linked to Pradaxa may include heart attack, stroke, and even death**. The USA Today reports the FDA has received over 3,781 reports of unfavorable Pradaxa side effects, which include about alleged 2,400 hemorrhages, 291 cases of acute renal failure, 640 strokes, and 542 deaths***.

Sources:
*http://www.nytimes.com/2012/11/03/business/a-rising-anti-stroke-drug-is-tied-to-risk-of-bleeding-deaths.html?_r=0
**http://www.fda.gov/Drugs/DrugSafety/ucm326580.htm
***usatoday30.usatoday.com/news/health/story/2012-08-19/pradaxa-blood-thinner-lawsuit/57134628/1

Pradaxa lawsuits have alleged the drug contained inadequate warnings, which did not fairly apprise patients of the serious health risks associated with the drug*. Pradaxa’s manufacturer, Boehringer Ingelheim, also faces wrongful death claims and on August 8, 2012, Pradaxa lawsuits were consolidated in the United States District Court for the Southern District of Illinois (MDL-2385)*. Over 150 cases with 165 plaintiffs have been included in this Pradaxa Multidistrict Litigation*. Recently, the judge overseeing this litigation issued an order requiring Boehringer Ingelheim to produce “Paper and Pradaxa-Specific Electronic Custodial files**.”

Sources:
*http://www.ilsd.uscourts.gov/mdl/mdl2385.aspx
**http://www.ilsd.uscourts.gov/Documents/mdl2385/cmo17.pdf

If you believe that you or one of your loved ones has been injured by Pradaxa, you may want to speak with a personal injury lawyer regarding a dangerous drug claim. A Pradaxa lawyer familiar with new developments in the investigation of the drug Pradaxa may be able to help you make important personal and legal decisions. d'Oliveira & Associates, P.C. is working with some of the leading Pradaxa lawyers and dangerous drug attorneys in the country who are handling these cases.

Please contact the law offices of d'Oliveira & Associates, P.C at 1-800-992-6878 or fill out a contact form for a free legal consultation.

Read the full story at http://www.prweb.com/releases/2013/3/prweb10418353.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. d’Oliveira & Associates Issues Webpage With Current Information On Stryker Hip Implant Lawsuits
2. d’Oliveira & Associates Releases Webpage With Current Information on Fresenius Lawsuits
3. d’Oliveira & Associates Releases Mirena IUD Infographic Describing Bayer’s Deceptive Mirena Simple Style Campaign
4. d’Oliveira & Associates Issues Webpage With Current Information On Mirena IUD Lawsuits
5. Research shows efficacy of treatment model developed at Women & Infants
6. Soy-based S-equol supplement reduces hot flash frequency, muscle & joint pain in US women
7. Vendors in Nevada, Michigan, & Illinois to be Featured on the PartyPOP.com Online Network
8. Beef & Pork Wholesaling in the US Industry Market Research Report Now Available from IBISWorld
9. The Tennessee Car Accident Lawyers at Michael D. Ponce & Associates Alert Public of CDC Survey Revealing Majority of High School Seniors Admitting to Texting Behind Wheel
10. Alex Galindo, Attorney and Partner at Curd, Galindo & Smith, LLP, Court Wins Against the County of Riverside's Motion to Dismiss Medical Malpractice Case
11. Play & Park Structures Included in New Play for All Abilities Playground
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... CA (PRWEB) , ... February 27, 2017 , ... ... serving San Francisco and environs, is proud to announce an upgrade to the ... on the upgraded Yelp page on topics as diverse as Platelet Rich Plasma ...
(Date:2/26/2017)... ... February 26, 2017 , ... NuevaCare, a leading home care agency based ... and Palo Alto, is proud to announce an important upgrade to its geographic information ... home care close to home, and by having city-specific pages, NuevaCare is answering that ...
(Date:2/26/2017)... ... February 26, 2017 , ... Functional imaging data supports improved ... study released today at the 1st Pan American Parkinson’s and Movement Disorders Congress. ... effective in improving cognitive function in PD patients. This study, led by Ibarretxe-Bilbao ...
(Date:2/24/2017)... ... 2017 , ... Only two months after the official release of The Private ... (France), XO Private has initiated a second print-run of its lavish luxury travel coffee ... across when open, weighs in at more than six kilos, retails at EUR 1,000 ...
(Date:2/24/2017)... ... ... In the Health Care IT campaign, Robert Herjavec discusses health IT security ... will be attacked, but when.” However, he and many others involved highlight a promising ... in auditing and monitoring have taken security in health care a very long way. ...
Breaking Medicine News(10 mins):
(Date:2/27/2017)... , Feb. 27, 2017  Interpace Diagnostics Group, ... provides clinically useful molecular diagnostic tests and pathology services, ... presented at the upcoming United States ... held March 4-10, 2017 in San Antonio, ... a review of data from the Company,s extensive experience ...
(Date:2/27/2017)... Fla. , Feb. 27, 2017 ... focused on developing cerebral embolic protection devices for ... the FDA,s Circulatory System Devices Panel that convened ... need for cerebral protection following transcatheter aortic valve ... by this FDA panel support the need for ...
(Date:2/27/2017)... 2017  RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the ... focused on tissue protection, repair and regeneration, today ... Ltd., received a positive response from the U.S. ... for RGN-137 to treat epidermolysis bullosa ("EB"). RGN-137 ... Thymosin beta 4 ("Tß4") as the active pharmaceutical ...
Breaking Medicine Technology: